Inflammatory Myofibroblastic Tumor

• Inflammatory Myofibroblastic Tumor is a rare, pseudo-tumoral lesion composed of myofibroblastic cells and inflammatory infiltrates.
• Symptoms are highly variable, depending on the tumor’s location, and often include pain, fever, or a palpable mass.
• Diagnosis relies on imaging studies followed by a definitive tissue biopsy and immunohistochemical analysis.
• The primary treatment is surgical removal, with other options like corticosteroids or targeted therapies considered for complex cases.

What is Inflammatory Myofibroblastic Tumor?

An Inflammatory Myofibroblastic Tumor (IMT) is a distinctive mesenchymal neoplasm that, despite its name, is generally considered to be of intermediate biological potential, meaning it is usually benign but can sometimes behave aggressively. It is characterized by a proliferation of spindle cells, which resemble fibroblasts and smooth muscle cells, intermingled with a prominent inflammatory infiltrate composed of plasma cells, lymphocytes, and eosinophils. IMTs can occur in virtually any organ, with the lungs, abdomen, and retroperitoneum being common sites, though they have been reported in various other locations including the head and neck, genitourinary tract, and extremities. The exact cause of IMT is not fully understood, but genetic alterations, particularly rearrangements involving the Anaplastic Lymphoma Kinase (ALK) gene, are found in a significant proportion of cases, suggesting a neoplastic rather than purely reactive process.

Symptoms and Diagnosis of Inflammatory Myofibroblastic Tumor

The presentation of inflammatory myofibroblastic tumor symptoms is highly variable and largely dependent on the tumor’s size and location. Common non-specific symptoms can include pain at the tumor site, fever, weight loss, and malaise. If the tumor compresses surrounding structures, it can lead to organ-specific symptoms; for example, a lung IMT might cause cough or shortness of breath, while an abdominal IMT could lead to abdominal pain or a palpable mass. In some cases, IMTs are discovered incidentally during imaging performed for other reasons.

The inflammatory myofibroblastic tumor diagnosis typically begins with imaging studies such as computed tomography (CT) scans, magnetic resonance imaging (MRI), or ultrasound, which can help locate the tumor and assess its size and relationship to surrounding tissues. However, definitive diagnosis requires a tissue biopsy. Pathological examination of the biopsy specimen is crucial, revealing the characteristic spindle cell proliferation and inflammatory infiltrate. Immunohistochemical staining often plays a key role, particularly in identifying ALK gene rearrangements, which can guide treatment decisions. Distinguishing IMT from other benign or malignant lesions with similar appearances is essential for accurate diagnosis and management.

Treatment Options for Inflammatory Myofibroblastic Tumor

The primary approach for inflammatory myofibroblastic tumor treatment options is complete surgical resection, whenever feasible. Surgical removal aims to excise the entire tumor with clear margins to minimize the risk of recurrence. For tumors that are small, easily accessible, and do not involve critical structures, surgery is often curative. However, the complexity of surgery can vary significantly depending on the tumor’s location and size, especially if it involves vital organs.

For patients with unresectable, recurrent, or metastatic IMT, or those who are not candidates for surgery, other treatment modalities may be considered. These can include:

• Corticosteroids: These anti-inflammatory drugs can sometimes reduce tumor size and alleviate symptoms, particularly in cases where inflammation is a prominent feature.
• Non-steroidal anti-inflammatory drugs (NSAIDs): Similar to corticosteroids, NSAIDs may help manage pain and inflammation associated with the tumor.
• Chemotherapy: Traditional chemotherapy agents are generally less effective for IMT, but they may be used in aggressive or metastatic cases, although responses can be variable.
• Targeted therapy: For IMTs with ALK gene rearrangements, ALK inhibitors (e.g., crizotinib) have shown significant efficacy, leading to tumor regression and improved outcomes in many patients. This represents a major advancement in the treatment of ALK-positive IMTs.

Regular follow-up is important after treatment to monitor for any signs of recurrence, which can occur even after complete surgical removal. The choice of treatment strategy is highly individualized, based on the tumor’s characteristics, location, the presence of ALK rearrangements, and the patient’s overall health.